Compare CVS Health Corp (CVS) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Lennar Corporation — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.49B), while Lennar Corporation trades at $77.5 (market cap $18.10B). The key difference: CVS Health Corp is far larger — about 6.2× Lennar Corporation's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Lennar Corporation for 67 Days on average.
| CVS | LEN | |
|---|---|---|
Market Cap | $112.49B | $18.10B |
Volume | 8,467,392 | 5,229,157 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $133.13 |
52-Week Low | $70.08 | $74.44 |
Typical Hold Time | 83 Days | 67 Days |
Enterprise Value | $174.83B | $22.52B |
Dividend Yield | 3.02% | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Lennar (LEN) trades at $77.60, showing modest daily gains amid bearish technical signals. The stock faces fundamental pressure with declining revenue and net income margins, though valuation metrics appear attractive with P/E of 14.42 and P/B below 1. Recent Q3 2026 earnings missed expectations, while Berkshire Hathaway's accumulating stake provides institutional support. Cash flow trends show operational challenges with negative net cash flow in 2025.
Investment outlook balances value opportunity against housing sector headwinds. The stock's below-book valuation and Berkshire's backing offer potential upside, but declining profitability and elevated mortgage rates pose significant risks. Analyst consensus leans cautiously optimistic with 46% buy ratings, though technical indicators suggest near-term bearish pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
